Shopping Cart
- Remove All
- Your shopping cart is currently empty
APE1-IN-2 (compound AP1), a Pt(IV) proagent, selectively targets the essential base excision repair protein apurinic/apyrimidinic endonuclease 1 (APE1). Exhibiting anticancer properties, APE1-IN-2 prompts the intracellular accumulation of platinum and initiates the activation of DNA damage response and apoptosis pathways [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $1,520 | 8-10 weeks | |
50 mg | $1,980 | 8-10 weeks | |
100 mg | $2,500 | 8-10 weeks |
Description | APE1-IN-2 (compound AP1), a Pt(IV) proagent, selectively targets the essential base excision repair protein apurinic/apyrimidinic endonuclease 1 (APE1). Exhibiting anticancer properties, APE1-IN-2 prompts the intracellular accumulation of platinum and initiates the activation of DNA damage response and apoptosis pathways [1]. |
In vitro | APE1-IN-2 (compound AP1) robustly suppresses malignant cell proliferation, including Cisplatin-resistant strains, exhibiting up to 18.11-fold greater inhibition than Cisplatin [1]. At 500 nM for 24 hours, it halts cell cycle progression in A549 and MCF7 cells [1], while at 10 μM for 24 hours, it induces p53-dependent apoptosis in A549 cells [1]. Additionally, APE1-IN-2 dose-dependently inhibits AP-cleavage activity with an IC50 of 45.14 ± 17.37 μM over 72 hours [1]. It directly targets APE1 endonuclease activity, disrupting miRNA processing and enhancing PTEN, a tumor suppressor gene expression [1]. |
In vivo | APE1-IN-2 (compound AP1) (2 mg/kg, IP, administered once every three days for 15 days) exhibits antitumor activity in the A549 xenograft model [1]. |
Molecular Weight | 522.21 |
Formula | C9H12Cl2N4O5Pt |
Cas No. | 2923433-95-6 |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.